Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)

Publikation

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)

Keune, Philipp M.; Cocks, Adam J.; Young, William R.; u. a. (2025): Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine), in: Bamberg: Otto-Friedrich-Universität, S. 1–8.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
Keune, Philipp M.
Cocks, Adam J.
Young, William R.
Burschka, Janina M.
Hansen, Sascha
Hofstadt-van Oy, Ulrich
Oschmann, Patrick
Muenssinger, Jana
Verlagsangabe
Otto-Friedrich-Universität : Bamberg
Erscheinungsjahr
2025
Quelle/Weitere Ausgabe
BMC Neurology, London: Springer Science and Business Media LLC (2015), Vol. 15, Nr. 1, pp. 1–8, ISSN: 1471-2377
Jahr der Erstpublikation
2015
Sprache(n)
Englisch
Lizenz
URN
Abstract

Background

Impaired walking capacity is a frequent confinement in Multiple Sclerosis (MS). Patients are affected by limitations in coordination, walking speed and the distance they may cover. Also abnormal dynamic walking patterns have been reported, involving continuous deceleration over time. Fampridine (4-aminopyridine), a potassium channel blocker, may improve walking in MS. The objective of the current study was to comprehensively examine dynamic walking characteristics and improved walking capacity in MS patients treated with fampridine.

Methods

A sample of N = 35 MS patients (EDSS median: 4) underwent an electronic walking examination prior to (Time 1), and during treatment with fampridine (Time 2). Patients walked back and forth a distance of 25 ft for a maximum period of 6 min (6-minute 25-foot-walk). Besides the total distance covered, average speed on the 25-foot distance and on turns was determined separately for each test minute, at Time 1 and Time 2.

Results

Prior to fampridine administration, 27/35 patients (77 %) were able to complete the entire 6 min of walking, while following the administration, 34/35 patients (97 %) managed to walk for 6 min. In this context, walking distance considerably increased and treatment was associated with faster walking and turning across all six test minutes (range of effect sizes: partial eta squared = .34-.72). Importantly, previously reported deceleration across test minutes was consistently observable at Time 1 and Time 2.

Discussion

Fampridine administration is associated with improved walking speed and endurance. Regardless of a treatment effect of fampridine, the previously identified, abnormal dynamic walking feature, i.e. the linear decline in walking speed, may represent a robust feature.

Conclusions

The dynamic walking feature might hence be considered as a candidate for a new outcome measure in clinical studies involving interventions other than symptomatic treatment, such as immune-modulating medication.

Trial registration

GND-Schlagwort(e)
Multiple Sklerose
Gehen
Freie Schlagwort(e)
Multiple sclerosis (MS)
Fampridine
4-aminopyridine
Walking capacity
Walking dynamics
Linear deceleration
6-minute walk
25-foot-walk
DDC-Klassifikation
150 Psychologie
RVK-Klassifikation
CZ 1380
Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
07.08.2025

Permalink: https://fis.uni-bamberg.de/handle/uniba/109430 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 16.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.